DUBLIN–(BUSINESS WIRE)–Jan 9, 2020–
The “Poliomyelitis – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 11, 5, 4, 3 and 3 respectively. Similarly, the Universities portfolio in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages comprises 1, 2, 4, 3 and 1 molecules, respectively.
Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
Reasons to buy
Key Topics Covered:
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/4wjfs4
View source version on businesswire.com:https://www.businesswire.com/news/home/20200109005630/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: INFECTIOUS DISEASES PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 01/09/2020 11:09 AM/DISC: 01/09/2020 11:09 AM
http://www.businesswire.com/news/home/20200109005630/en